Granulocyte activation and adhesion molecules during hemodialysis with cuprophane and a high-flux biocompatible membrane.
Hemodialysis with complement-activating membranes, such as cuprophane, induces neutropenia and expression of the granulocyte adhesion receptor Mac-1 (CD11b/CD18), while hemodialysis with noncomplement-activating membranes does not. Increased expression of CD11b by neutrophils may mediate cuprophane-induced leukopenia. However, the rebound granulocytosis that follows leukopenia is not fully understood. Ten patients on regular hemodialysis were included in a cross-over study. Hemodialysis was performed for 2 weeks with cuprophane and 2 weeks with polyamide, a high-flux noncomplement-activating membrane. At the end of each period, the following parameters were determined during a hemodialysis session: C5a concentration by enzyme immunoassay and the neutrophil expression of CD11b, LFA-1 (CD11a/CD18), and the antigen recognized by MoF11 (MoF11 Ag), a monoclonal antibody that recognizes activated neutrophils, by immunofluorescence flow cytometry. Hemodialysis with cuprophane induced an increase in C5a concentration and in the expression of CD11b and MoF11 Ag, which were maximal after 15 minutes of hemodialysis, at the nadir of neutropenia. CD11b expression was maintained throughout hemodialysis, despite the reversal of neutropenia. Conversely, after peak expression, C5a and MoF11 Ag decreased as the neutrophil count increased to baseline values. Polyamide hemodialysis did not induce variations in C5a concentration, nor in CD11b and MoF11 Ag expression. CD11a/CD18 expression remained stable during hemodialysis with both membrane types. Neutrophil activation, as determined by MoF11 Ag expression, was correlated with the evolution of neutrophil count and C5a concentration during cuprophane hemodialysis, while CD11b expression was not correlated with neutrophil count throughout dialysis. A decrease in neutrophil activation could explain in part the detachment of neutrophils previously bound to endothelium and, therefore, the reversal of neutropenia.(ABSTRACT TRUNCATED AT 250 WORDS)
Combe
C
C
Service d'Hémodialyse, Hôpital Pellegrin, Bordeaux, France.
Pourtein
M
M
de Précigout
V
V
Baquey
A
A
Morel
D
D
Potaux
L
L
Vincendeau
P
P
Bézian
J H
JH
Aparicio
M
M
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D001672:Biocompatible Materials; D015815:Cell Adhesion Molecules / Q000502:physiology*; D002482:Cellulose / Q000031:analogs & derivatives*; D015936:Complement C5a; D005260:Female; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D006098:Granulocytes / Q000276:immunology / Q000502:physiology*; D006801:Humans; D008297:Male; D008567:Membranes, Artificial; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects* / Q000379:methods
D000911:Antibodies, Monoclonal; D001672:Biocompatible Materials; D015815:Cell Adhesion Molecules; D008567:Membranes, Artificial; D015936:Complement C5a; D002482:Cellulose; C009865:cuprammonium cellulose